Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

prnasiaMarch 29, 2021

Tag: Saxenda , CHMP , Novo Nordisk , obesity

PharmaSources Customer Service